News and Trends 6 Jan 2023
C2i Genomics extends AstraZeneca cancer deal
C2i Genomics, a cancer intelligence company, today announced an extension of a collaboration with AstraZeneca. The two companies have collaborated to evaluate the potential of whole-genome minimal residual disease (MRD)…